SurModics (SRDX) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. BBIO
5. NVDA
6. GOOGL
7. OPCH
8. CHRW
9. AMD
10. HUBS

Go back to SurModics (SRDX) Tops Q1 EPS by 7c

Surmodics Reports First Quarter Fiscal 2021 Results

February 9, 2021 7:30 AM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020.

Summary of First Quarter and Recent Highlights

Revenue of $22.3 million, a decrease of 1% year-over-year GAAP EPS of ($0.02), non-GAAP EPS of $0.02 SurVeil drug-coated balloon (DCB) pivotal clinical trial meets both primary endpoints to demonstrate non-inferior safety and efficacy vs. IN.PACT® Admiral® DCB Achieved $15 million TRANSCEND clinical report milestone under the SurVeil... More